We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
In the latest trading session, Novo Nordisk (NVO - Free Report) closed at $54.87, marking a +1.05% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.05%. Meanwhile, the Dow lost 0.59%, and the Nasdaq, a tech-heavy index, added 0.45%.
The drugmaker's stock has climbed by 6.58% in the past month, falling short of the Medical sector's gain of 7.77% and outpacing the S&P 500's gain of 3.44%.
The upcoming earnings release of Novo Nordisk will be of great interest to investors. The company's earnings report is expected on November 5, 2025. The company is predicted to post an EPS of $0.95, indicating a 5.56% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $12.06 billion, indicating a 14.77% increase compared to the same quarter of the previous year.
NVO's full-year Zacks Consensus Estimates are calling for earnings of $3.85 per share and revenue of $48.52 billion. These results would represent year-over-year changes of +17.38% and +15.25%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novo Nordisk. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.18% lower. Novo Nordisk is currently a Zacks Rank #4 (Sell).
Valuation is also important, so investors should note that Novo Nordisk has a Forward P/E ratio of 14.12 right now. This denotes a discount relative to the industry average Forward P/E of 14.2.
Also, we should mention that NVO has a PEG ratio of 2.06. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. NVO's industry had an average PEG ratio of 1.61 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 97, positioning it in the top 40% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Novo Nordisk (NVO - Free Report) closed at $54.87, marking a +1.05% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.05%. Meanwhile, the Dow lost 0.59%, and the Nasdaq, a tech-heavy index, added 0.45%.
The drugmaker's stock has climbed by 6.58% in the past month, falling short of the Medical sector's gain of 7.77% and outpacing the S&P 500's gain of 3.44%.
The upcoming earnings release of Novo Nordisk will be of great interest to investors. The company's earnings report is expected on November 5, 2025. The company is predicted to post an EPS of $0.95, indicating a 5.56% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $12.06 billion, indicating a 14.77% increase compared to the same quarter of the previous year.
NVO's full-year Zacks Consensus Estimates are calling for earnings of $3.85 per share and revenue of $48.52 billion. These results would represent year-over-year changes of +17.38% and +15.25%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novo Nordisk. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.18% lower. Novo Nordisk is currently a Zacks Rank #4 (Sell).
Valuation is also important, so investors should note that Novo Nordisk has a Forward P/E ratio of 14.12 right now. This denotes a discount relative to the industry average Forward P/E of 14.2.
Also, we should mention that NVO has a PEG ratio of 2.06. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. NVO's industry had an average PEG ratio of 1.61 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 97, positioning it in the top 40% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.